It’s a drug meant for the injection-weary diabetic set: Dance Biopharma‘s developing an inhalable form of insulin, and a series accompanying electric devices to dispense the aerial hormone – meant to go up against MannKind’s Afrezza.
The Bay Area company’s now in the midst of a $15 million debt fundraise, having brought in about $5 million thus far in this round. This is its first ask for cash since Dance Biopharma scrapped plans for a $75 million IPO in October, citing unfavorable market conditions.
Help employers find you! Check out all the jobs and post your resume.
